Synthetic HLA binding peptide analogues and uses thereof

Abstract

The present invention is directed to immunogenic bcr-abl-based peptides, compositions and vaccines comprising same, and methods of use thereof for treating, inhibiting or reducing the incidence of a bcr-abl-expressing cancer, and methods of generating a heteroclitic immune response against, or cytotoxic T cells specifically recognizing bcr-abl-expressing cancer cells.

Dependencies are inferred from the claim text.